Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Citi
Farmers Insurance
Fish and Richardson
McKesson
Covington
Colorcon
Deloitte
Argus Health

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021160

« Back to Dashboard
NDA 021160 describes PHOSLO GELCAPS, which is a drug marketed by Fresenius Medcl and is included in one NDA. It is available from six suppliers. There are two patents protecting this drug. Additional details are available on the PHOSLO GELCAPS profile page.

The generic ingredient in PHOSLO GELCAPS is calcium acetate. There are two hundred and seventy drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

Summary for NDA: 021160

Tradename:
2
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Genitourinary Agents
Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Pharmacology for NDA: 021160

Suppliers and Packaging for NDA: 021160

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PHOSLO
calcium acetate
CAPSULE;ORAL 021160 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2081 0781-2081-02 200 CAPSULE in 1 BOTTLE (0781-2081-02)
PHOSLO
calcium acetate
CAPSULE;ORAL 021160 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2672 0781-2672-02 200 CAPSULE in 1 BOTTLE (0781-2672-02)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength333.5MG
Approval Date:Apr 2, 2001TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength667MG
Approval Date:Apr 2, 2001TE:RLD:No
Patent:► SubscribePatent Expiration:Apr 3, 2021Product Flag?Substance Flag?Delist Request?

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength667MG
Approval Date:Apr 2, 2001TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Apr 3, 2021Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021160

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-001Apr 2, 2001► Subscribe► Subscribe
Fresenius Medcl
PHOSLO GELCAPS
calcium acetate
CAPSULE;ORAL021160-003Apr 2, 2001► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-002Apr 2, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
Boehringer Ingelheim
Cantor Fitzgerald
Fuji
Teva
Novartis
Julphar
Queensland Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot